for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-I-Mab Says Abbvie Has A Right Of First Negotiation To In-License Further Development And Commercialization Of 2 Additional Lemzoparlimab-Based Bispecific Antibodies- Conf. Call

Sept 4 (Reuters) - I-Mab:

* SAYS POTENTIAL VALUE OF SUCH LICENSE OF THE 2 BISPECIFIC PROGRAMS IS A MINIMUM $1 BILLION IN UPFRONT AND MILESTONE PAYMENTS- CONF. CALL

* SAYS ABBVIE HAS A RIGHT OF FIRST NEGOTIATION TO IN-LICENSE FURTHER DEVELOPMENT AND COMMERCIALIZATION OF 2 ADDITIONAL LEMZOPARLIMAB-BASED BISPECIFIC ANTIBODIES- CONF. CALL Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up